Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
664 A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)
Compose a Response to This Article
Other responses
No responses have been published for this article.